Data Sheet 1_Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.docx

Data Sheet 1_Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.docx

Introduction<p>The combination of anti-angiogenic agents, PD-1/L1 inhibitors, and hepatic arterial infusion chemotherapy (HAIC) has emerged as an important strategy for unresectable hepatocellular carcinoma (uHCC), yet comparative data on efficacy and safety between different anti-angiogenic a...

Full description

Saved in:
Bibliographic Details
Main Author: Lichang Huang (21412778) (author)
Other Authors: Yujie Xu (1766401) (author), Na Liu (102929) (author), Hailong Chen (436622) (author), Zichao Wu (12735888) (author), Qijiong Li (14032517) (author), Minqiang Lu (10279616) (author), Wei Wei (21173) (author), Yaojun Zhang (389482) (author), Minshan Chen (151567) (author), Li Xu (108702) (author), Ming Shi (78991) (author), Zhicheng Lai (14032511) (author)
Published: 2025
Subjects:
Genetic Immunology
hepatocellular carcinoma
lenvatinib
bevacizumab
combination therapy
potential resectable
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items